Residency · Pittsburgh, PA
Sponsored by UPMC Medical Education
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
The Lancet. Respiratory medicine · 2021 · 293 citations · Sally Wenzel
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
JAMA dermatology · 2023 · 129 citations · Chitra Natalie
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
The British journal of dermatology · 2023 · 134 citations · Chitra Natalie
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
The New England journal of medicine · 2023 · 105 citations · Todd Green
Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
The journal of allergy and clinical immunology. In practice · 2024 · 64 citations · Merritt Fajt
Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time.
American journal of respiratory and critical care medicine · 2022 · 131 citations ·
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
The Lancet. Respiratory medicine · 2021 · 130 citations · Sally Wenzel
15LO1 dictates glutathione redox changes in asthmatic airway epithelium to worsen type 2 inflammation.
The Journal of clinical investigation · 2022 · 108 citations · Sally Wenzel